ArticleInternational journal of particle therapy2026
Commissioning and Validation of a Synchrocyclotron - Based Ultra-High-Dose-Rate Beamline for FLASH.
Article in International journal of particle therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Purpose: FLASH radiotherapy delivers ultra-high dose rate radiation (>40 Gy/s) has shown promise in reducing normal tissue toxicity while maintaining tumor control. IBA's single-room proton system, equipped with S2C2 superconducting synchrocyclotron accelerator, has recently demonstrated to achieve UHDR delivery. Integrating the UHDR beam line in the treatment planning system (TPS) is crucial for accurate dose calculation in preclinical study, optimization of the 2D dose profile as well as paving the way for further accessory development for spread-out Bragg peak FLASH. This study aims to commission and validate a synchrocyclotron-based pencil beam scanning UHDR proton beamline on the IBA ProteusONE system in RayStation TPS. The goal is to establish a framework for TPS modeling and validation, facilitating preclinical FLASH radiotherapy studies. Methods: The transmission UHDR beamline using scanning proton beam energy of 228 MeV was characterized at gantry 0° using comprehensive point dose and 2D lateral profiles measurements. The beam model was developed in RayStation, incorporating key parameters such as virtual source position, spot size, integrated depth dose (IDD), and absolute dose calibration. Extensive validations were conducted using ionization chambers, film dosimetry, and 2D scintillation detectors, with gamma analysis performed to assess the accuracy of the TPS model with open field and field in the presence of brass apertures. Results: The UHDR beamline achieved ultra-high dose rates exceeding 40 Gy/s (average dose rate for a 2.5 x 2.5 cm field) with consistent dose output validated across multiple detectors. The nozzle current was measured to be linear with respect to the requested MU in the range of 45 to 126 nA. The RayStation beam model demonstrated excellent agreement with experimental measurements, achieving less than 2.5% deviation for all point dose measurements. For 2D profile measurements, gamma passing rates >95% under 2%/2 mm criteria for all fields. The TPS allowed optimization of the spot pattern for UHDR FLASH beams aligned closely with clinical beam profiles, enabling accurate preclinical study comparisons. Conclusions: A synchrocyclotron-based UHDR beamline was successfully commissioned and validated through a reliable TPS model for transmission FLASH application. The results provide a foundation for preclinical FLASH-RT research and future clinical applications, demonstrating the feasibility of integrating FLASH-RT into existing proton therapy platforms. Future work will extend the commissioning to all gantry angles and explore spread-out Bragg peak FLASH delivery for improved dose conformality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.